BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34624408)

  • 1. Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis.
    Viani GA; Gouveia AG; Louie AV; Korzeniowski M; Pavoni JF; Hamamura AC; Moraes FY
    Radiother Oncol; 2021 Nov; 164():245-250. PubMed ID: 34624408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
    Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
    Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.
    Lehrer EJ; Singh R; Wang M; Chinchilli VM; Trifiletti DM; Ost P; Siva S; Meng MB; Tchelebi L; Zaorsky NG
    JAMA Oncol; 2021 Jan; 7(1):92-106. PubMed ID: 33237270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
    Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
    Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial.
    David S; Tan J; Savas P; Bressel M; Kelly D; Foroudi F; Loi S; Siva S
    Breast; 2020 Feb; 49():55-62. PubMed ID: 31734589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Reirradiation With Stereotactic Ablative Radiotherapy of Lung Cancer After a First Course of Thoracic Radiation: A Meta-analysis.
    Viani GA; Arruda CV; De Fendi LI
    Am J Clin Oncol; 2020 Aug; 43(8):575-581. PubMed ID: 32554982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis.
    Safavi AH; Mak DY; Boldt RG; Chen H; Louie AV
    Lung Cancer; 2021 Oct; 160():179-186. PubMed ID: 34330566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-fraction stereotactic ablative body radiotherapy for sternal metastases in oligometastatic breast cancer: Technique and single institution experience.
    Li MP; Kelly D; Tan J; Siva S; Kron T; David S
    J Med Imaging Radiat Oncol; 2020 Aug; 64(4):580-585. PubMed ID: 32588550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer.
    Wijetunga NA; Dos Anjos CH; Zhi WI; Robson M; Tsai CJ; Yamada Y; Dover L; Gillespie EF; Xu AJ; Yang JT
    Cancer Med; 2021 Aug; 10(15):5163-5174. PubMed ID: 34159748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.
    Li M; Yang X; Chen Y; Yang X; Dai X; Sun F; Zhang L; Zhan C; Feng M; Wang Q
    Onco Targets Ther; 2017; 10():2885-2892. PubMed ID: 28652770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines.
    Bae SH; Chun SJ; Chung JH; Kim E; Kang JK; Jang WI; Moon JE; Roquette I; Mirabel X; Kimura T; Ueno M; Su TS; Tree AC; Guckenberger M; Lo SS; Scorsetti M; Slotman BJ; Kotecha R; Sahgal A; Louie AV; Kim MS
    Int J Radiat Oncol Biol Phys; 2024 Feb; 118(2):337-351. PubMed ID: 37597757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes.
    Shanker MD; Moodaley P; Soon W; Liu HY; Lee YY; Pryor DI
    J Med Imaging Radiat Oncol; 2021 Dec; 65(7):956-968. PubMed ID: 34396706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the Outcomes of Stereotactic Ablative Radiotherapy and Non-Stereotactic Ablative Radiotherapy Definitive Radiotherapy Approaches to Thoracic Malignancy: A Systematic Review and Meta-Analysis.
    Hegi F; D'Souza M; Azzi M; De Ruysscher D
    Clin Lung Cancer; 2018 May; 19(3):199-212. PubMed ID: 29370978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines.
    Mayinger M; Kotecha R; Sahgal A; Kim MS; Lo SS; Louie AV; Scorsetti M; Slotman B; Guckenberger M
    Lung Cancer; 2023 Aug; 182():107284. PubMed ID: 37390723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
    Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.
    Chalkidou A; Macmillan T; Grzeda MT; Peacock J; Summers J; Eddy S; Coker B; Patrick H; Powell H; Berry L; Webster G; Ostler P; Dickinson PD; Hatton MQ; Henry A; Keevil S; Hawkins MA; Slevin N; van As N
    Lancet Oncol; 2021 Jan; 22(1):98-106. PubMed ID: 33387498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
    Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.